Buckle C - Search Results

1

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway.

Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I. Xu S, et al. Among authors: buckle c. Leukemia. 2012 Dec;26(12):2546-9. doi: 10.1038/leu.2012.126. Epub 2012 May 8. Leukemia. 2012. PMID: 22652628 No abstract available.

2

A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.

Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R, Singh N, Glassford J, Otsuki T, Nathwani AC, Croucher PI, Yong KL. Rabin N, et al. Among authors: buckle c. Leukemia. 2007 Oct;21(10):2181-91. doi: 10.1038/sj.leu.2404814. Epub 2007 Jul 26. Leukemia. 2007. PMID: 17657224

3

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.

Buckle CH, De Leenheer E, Lawson MA, Yong K, Rabin N, Perry M, Vanderkerken K, Croucher PI. Buckle CH, et al. PLoS One. 2012;7(8):e41127. doi: 10.1371/journal.pone.0041127. Epub 2012 Aug 29. PLoS One. 2012. PMID: 22952578 Free PMC article.

4

Targeting RANK/RANKL in the treatment of solid tumours and myeloma.

Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA. Buckle CH, et al. Curr Pharm Des. 2010;16(11):1272-83. doi: 10.2174/138161210791034021. Curr Pharm Des. 2010. PMID: 20166980 Review.

5

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI. Heath DJ, et al. J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104. J Bone Miner Res. 2009. PMID: 19016584 Free article.

6

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.

Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA, Chantry AD. Lath DL, et al. PLoS One. 2018 Jun 20;13(6):e0199517. doi: 10.1371/journal.pone.0199517. eCollection 2018. PLoS One. 2018. PMID: 29924867 Free PMC article.

7

Myeloma bone disease: pathogenesis, current treatments and future targets.

Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD. Walker RE, et al. Br Med Bull. 2014 Sep;111(1):117-38. doi: 10.1093/bmb/ldu016. Br Med Bull. 2014. PMID: 25190762 Review.

8

Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.

Talley PJ, Chantry AD, Buckle CH. Talley PJ, et al. Br Med Bull. 2015 Mar;113(1):15-30. doi: 10.1093/bmb/ldu041. Epub 2015 Feb 6. Br Med Bull. 2015. PMID: 25662536 Review.

9

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.

Cross NA, Waterman EA, Jokonya N, Fowles A, Buckle CH, Phillips J, Holen I, Hamdy FC, Eaton CL. Cross NA, et al. Among authors: buckle ch. J Cell Biochem. 2008 Jul 1;104(4):1452-64. doi: 10.1002/jcb.21721. J Cell Biochem. 2008. PMID: 18320583

10

The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells.

AlShaibi HF, Ahmed F, Buckle C, Fowles ACM, Awlia J, Cecchini MG, Eaton CL. AlShaibi HF, et al. Among authors: buckle c. Biotechnol Appl Biochem. 2018 May;65(3):407-418. doi: 10.1002/bab.1619. Epub 2017 Nov 2. Biotechnol Appl Biochem. 2018. PMID: 28981962

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters